Employees: 674
Size Valneva (VLA.PA) is a France Health Care company (Biotechnology) with a market value of $508M, the 175th largest of 206 France companies the cockpit tracks. Shares closed at €2.43 on 18 Nov 2026.
Performance Over six months the shares fell 5.6%, against -14.1% for the median peer and -2.1% for the France market (cap-weighted) — 8th highest of 18 in its peer set.
Growth Revenue fell 27.2% over the last twelve months (peer median +3.1%); the operating margin is -86.7% (peer median -0.2%).
Valuation It trades at 3.9× enterprise value to sales against a peer median of 6.2× (5th cheapest of 14).
Capital Return on invested capital runs 64.1 points below its cost of capital (10.0% WACC).
Next results Next results expected around 24 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €143M | €175M | €170M | €154M | €361M |
| Revenue growth | — | +3% | +10% | -57% | — |
| Gross profit | €23.4M | €62.7M | €63.6M | €48.5M | €32.0M |
| EBITDA | -€103M | -€70.2M | -€79.0M | -€86.5M | -€105M |
| Net income | -€158M | -€115M | -€12.2M | -€101M | -€143M |
| Free cash flow | -€87.3M | -€86.2M | -€98.7M | -€228M | -€284M |
| Capital expenditure | €2.35M | €4.48M | €16.4M | €14.3M | €29.3M |
| Total debt | €210M | €207M | €216M | €209M | €152M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VLA.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.3% | -10.2% | 7th highest of 21 |
| 6-month return | -5.6% | -14.1% | 8th highest of 18 |
| Distance from 52-week high | -52.8% | -44.6% | 7th lowest of 21 |
| Revenue growth (TTM) | -27.2% | +3.1% | 4th lowest of 13 |
| Operating margin | -86.7% | -0.2% | 5th lowest of 14 |
| EV / Sales | 3.9× | 6.2× | 5th cheapest of 14 |
| ROIC minus cost of capital | -64.1 pp | -3.8 pp | 3rd lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |